Alisa Dietl brings her international training and clinical perspective to Gladstone, where she works to engineer more effective cancer immunotherapies for solid tumors.

Engineered cellular immunotherapy shows great potential for treating autoimmune diseases. Payne and colleagues review emerging clinical data of the most recently developed technologies.

A molecule that engages both antibodies and tumor cells may piggyback cancer killing atop a robust antiviral immune response. Image credit:© iStock.com, ALIOUI Mohammed Elamine Immune cells in the tumor microenvironment often function just fine, but cancer cells have various means to evade detection, making them difficult to eradicate. Cancer researcher Fan Zou from Shenzhen University of Advanced Technology wondered, what if scientists could harness the body’s naturally robust immune response: antiviral immunity? In a recent study, Zou and his colleagues designed a “bridge” molecule that tags cancer cells with a varicella virus antigen.1 This allowed antibodies produced in response to the chickenpox vaccine, which…

Abstract

Engineered cellular immunotherapy shows great potential for treating autoimmune diseases. Payne and colleagues review emerging clinical data of the most recently developed technologies.

Des chercheurs montréalais ont identifié à la surface des cellules cancéreuses de nouvelles cibles qui pourraient être exploitées par de futures immunothérapies ultraciblées, ouvrant de nouvelles poss...

Davenport, A. J. et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol. Res. 3, 483–494 (2015). Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011). Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018). Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019). Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020). Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020). Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219–2230 (2024). Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021). San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory...

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

Montreal researchers have identified new targets on the surface of cancer cells that could be exploited by future ultra-targeted immunotherapies, opening up new treatment possibilities.

La taille du marché de l’immunothérapie contre les virus oncolytiques a été estimée à 3,33 (milliards USD) en 2023. L’industrie du marché de l’immunothérapie contre les virus oncolytiques devrait pass...

Une équipe de recherche a découvert un frein interne du système immunitaire, SLAMF6, et mis au point des anticorps pour le neutraliser. Des résultats prometteurs ont été obtenus chez la souris.